

2011

Investigation of 95 variants identified in a genome-wide study for association with mortality after acute coronary syndrome

Thomas M. Morgan
Vanderbilt University

John A. House
University of Missouri - Kansas City

Sharon Cresci
Washington University School of Medicine in St. Louis

Philip Jones
University of Missouri - Kansas City

Hooman Allayee
University of Southern California

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs



Part of the [Medicine and Health Sciences Commons](#)

Please let us know how this document benefits you.

Recommended Citation

Morgan, Thomas M.; House, John A.; Cresci, Sharon; Jones, Philip; Allayee, Hooman; Hazen, Stanley L.; Patel, Yesha; Patel, Riyaz S.; Eapen, Danny J.; Waddy, Salina P.; Quyyumi, Arshed A.; Kleber, Marcus E.; Marz, Winfried; Winkelmann, Bernhard R.; Boehm, Bernhard O.; Krumholz, Harlan M.; and Spertus, John A., "Investigation of 95 variants identified in a genome-wide study for association with mortality after acute coronary syndrome." *BMC Medical Genetics*. 12, 127. (2011).
https://digitalcommons.wustl.edu/open_access_pubs/411

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors

Thomas M. Morgan, John A. House, Sharon Cresci, Philip Jones, Hooman Allayee, Stanley L. Hazen, Yesha Patel, Riyaz S. Patel, Danny J. Eapen, Salina P. Waddy, Arshed A. Quyyumi, Marcus E. Kleber, Winfried Marz, Bernhard R. Winkelmann, Bernhard O. Boehm, Harlan M. Krumholz, and John A. Spertus

RESEARCH ARTICLE

Open Access

Investigation of 95 variants identified in a genome-wide study for association with mortality after acute coronary syndrome

Thomas M Morgan^{1*}, John A House², Sharon Cresci³, Philip Jones², Hooman Allayee⁴, Stanley L Hazen⁵, Yesha Patel⁴, Riyaz S Patel^{6,7}, Danny J Eapen⁶, Salina P Waddy⁸, Arshed A Quyyumi⁶, Marcus E Kleber⁹, Winfried März¹⁰, Bernhard R Winkelmann¹¹, Bernhard O Boehm¹², Harlan M Krumholz⁴ and John A Spertus²

Abstract

Background: Genome-wide association studies (GWAS) have identified new candidate genes for the occurrence of acute coronary syndrome (ACS), but possible effects of such genes on survival following ACS have yet to be investigated.

Methods: We examined 95 polymorphisms in 69 distinct gene regions identified in a GWAS for premature myocardial infarction for their association with post-ACS mortality among 811 whites recruited from university-affiliated hospitals in Kansas City, Missouri. We then sought replication of a positive genetic association in a large, racially diverse cohort of myocardial infarction patients (N = 2284) using Kaplan-Meier survival analyses and Cox regression to adjust for relevant covariates. Finally, we investigated the apparent association further in 6086 additional coronary artery disease patients.

Results: After Cox adjustment for other ACS risk factors, of 95 SNPs tested in 811 whites only the association with the rs6922269 in *MTHFD1L* was statistically significant, with a 2.6-fold mortality hazard ($P = 0.007$). The recessive A/A genotype was of borderline significance in an age- and race-adjusted analysis of the entire combined cohort (N = 3095; $P = 0.052$), but this finding was not confirmed in independent cohorts (N = 6086).

Conclusions: We found no support for the hypothesis that the GWAS-identified variants in this study substantially alter the probability of post-ACS survival. Large-scale, collaborative, genome-wide studies may be required in order to detect genetic variants that are robustly associated with survival in patients with coronary artery disease.

Background

Genome-wide association studies (GWAS) have identified robust genetic associations in a variety of common diseases [1], including myocardial infarction (MI) [2-6]. The GWAS approach, with its emphasis on large sample sizes and inclusion of hundreds of thousands of genetic markers, has produced a degree of reproducibility that was generally lacking in earlier candidate gene studies of MI [7]. However, nine GWAS-identified genetic susceptibility markers, all meeting criteria for genome-wide statistical significance, collectively account for only 3% of

the estimated heritability of early-onset myocardial infarction (MI), raising questions about the clinical utility of such markers for predicting MI [1].

In contrast to the identification of risk markers for incident disease, risk-stratifying patients with established disease, including those who have suffered an MI, is a cornerstone of modern cardiovascular care. Yet association studies of GWAS-generated candidate genes with prognosis following acute coronary syndromes (ACS), including unstable angina, non-ST elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI), require resource-intensive longitudinal designs and have rarely been performed. Although the post-ACS period is considered high risk, there is substantial heterogeneity in patient outcomes, and

* Correspondence: thomas.morgan@vanderbilt.edu

¹Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN USA

Full list of author information is available at the end of the article

genetic markers could potentially be useful in defining risk, guiding treatment, and understanding the mechanisms of recurrent events and mortality. In contrast to genetic screening for incident MI, which requires screening large populations of patients without recognized disease, prognostically important genetic variations after an ACS could accelerate translation to clinical practice by focusing upon a narrower cohort of patients at high risk. Moreover, the identification of genetic pathways leading to a poor prognosis following ACS may identify new pathways of disease progression that could become novel targets for the chemoprevention of recurrent ACS.

GWAS-identified risk factors for incident MI pose an important opportunity to identify genetic markers of prognosis in an ACS population, given the clinical logic that a validated risk factor for MI occurrence may also lead to more rapid disease progression after an initial event. To test this possibility, we selected as a pool of candidate prognostic markers the 95 most statistically significant of approximately 2.5 million genetic variants tested in a GWAS of premature MI occurrence (Myocardial Infarction Genetics Consortium) [5]. We specifically tested the hypothesis that these risk markers for MI would be associated with all-cause mortality within 3 years following ACS.

Methods

Identification of Candidate Genes

We tested 95 SNPs in 63 individual genes, and an additional 6 distinct gene regions containing more than one genetic locus. The 95 candidate SNPs were ranked the most statistically significant ($P < 1 \times 10^{-5}$) of all ~2.5 million SNPs that were included on, or imputed from, the Affymetrix 6.0 microarray and brought forward into replication stage 3 of the Myocardial Infarction Genetics Consortium Study [5].

Study Population and Genotyping

Our study design called for testing genetic markers for prognostic association with 3-year mortality in an ACS cohort, and attempting replication of significant associations in additional cohorts of MI and/or coronary artery disease (CAD) patients. The discovery cohort was comprised of 811 self-reported white patients of European ancestry with ACS who were identified from a consecutive series of patients presenting to two Kansas City, MO hospitals (Mid-America Heart Institute and Truman Medical Center), from March 2001 through June 2003. Standard definitions were used to diagnose ACS patients with either myocardial infarction or unstable angina [8,9]. Individuals were monitored for incident deaths from any cause, as determined by periodic queries of the Social Security Administration Death

Master File [10]. Follow-up was planned for a minimum of 3-years.

The Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status Study (TRIUMPH) served as the replication cohort, as described in a recent publication [11]. This study recruited several sites that were enriched for African-American patients with MI and was specifically designed to address racial disparities in outcomes, including genetic variations between races. Patients were adults > 18 years of age with elevated cardiac biomarkers (troponin or creatine kinase-MB fraction) as well as other clinical evidence of MI (ECG ST-segment changes or prolonged ischemia signs/symptoms). Collected data included baseline chart abstractions for demographic and medical history, followed by study coordinators contacting patients for follow-up interviews at 1, 6, and 12 months after MI. Long-term mortality was assessed by periodic queries of the Social Security Administration Death Master File [10].

Additional validation cohorts for survival analysis involving one SNP, rs6922269 in the *MTHFD1L* gene, were provided by Cleveland Clinic GeneBank (coronary artery disease including acute myocardial infarction) [12,13], Emory Cardiology Biobank (cardiac catheterization patients) [14], and the Ludwigshafen Risk and Cardiovascular Health (LURIC) study (patients hospitalized for coronary angiography) [15]. Clinical details of the cohorts are described in Appendix A.

Genotyping of the 95 SNPs was performed at the Broad Institute at MIT using the iPLEX MassARRAY platform (Sequenom) on extracted leukocyte DNA (TRIUMPH) or whole genome amplified DNA (Mid-America Heart cohort) [16,17]. More extensive details of the cases, DNA extraction methods, and genotyping procedures have been recently described [5,7,18]. Flanking DNA sequence and other identifiers for each genetic variant are available upon request from the authors.

Statistical Analysis

Genotype distributions were examined for significant deviations ($P < 0.05$) from Hardy-Weinberg equilibrium (HWE). Chi-square testing was used to screen for possible HWE violations, which were further investigated for statistically significant departure from HWE expectations by Monte Carlo testing involving 10,000 random reshufflings of alleles [19].

Initially, Kaplan-Meier survival analysis was performed for each variant using SPSS 17.0 (Chicago, IL). The equality of survival curves was tested by the log-rank test pooled over all genotypic strata (one degree of freedom). If the log-rank P value was < 0.05 , then pairwise log-rank tests were performed to explore which genotype or genotypes were most likely to confer mortality

risk. Cox regression models were then used to adjust positive associations for age, sex, hypertension, ACS type, prior myocardial infarction, prior revascularization, congestive heart failure, diabetes, renal failure, marital status, educational level, menopause, and smoking and alcohol use prior to the ACS. We tested proportional-hazards assumption for each covariate using Schoenfeld residuals. We report raw *P* values and considered the conservative Bonferroni correction ($0.05/95 = 0.0005$) to represent the study-wide statistical significance threshold [20], but in addition to considering chance, we also considered canonical epidemiological principles of causation, including magnitude of effect, allelic dose-response, and adjustment for confounding.

Our sample had 93% power to detect an association, by the log rank test ($P < 0.05$), for a hazard ratio of 2.5 or higher, given a frequent genotype (0.5), and 80% power to detect a hazard ratio of 3.3 or higher, given an infrequent genotype (0.1) [21]. Given that genetic variants conferring more modest effects may not reach the conventional statistical significance level of $P < 0.05$, we sought to explore the possibility that null results might be related to lack of power (type II error), by examining the characteristics of the overall *P* value distribution by visualizing a Q-Q plot (quantile-quantile) using SPSS 17.0 (Chicago, IL).

Results

The clinical characteristics of the 811 cases are described in Table 1. The population of ACS cases included 308 STEMI (38%), 284 NSTEMI (35%), and

Table 1 Characteristics of 811 White Subjects with Acute Coronary Syndrome at Baseline

Characteristic	Male ACS Cases (N = 550)	Female ACS Cases (N = 261)
Mean age in years (SD)	60.7 (12.5)	63.1 (13.2)
Mean body mass index (SD)	29.1 (5.5)	29.9 (6.9)
Family history of CAD/MI (%)	279 (50.7)	135 (51.7)
Prior myocardial infarction (%)	142 (25.8)	74 (28.4)
Prior revascularization (%)	205 (37.3)	83 (31.8)
Congestive heart failure (%)	23 (4.2)	18 (6.9)
Hypertension (%)	305 (55.5)	182 (69.7)
Diabetes Mellitus (%)	116 (21.1)	77 (29.5)
Hypercholesterolemia (%)	314 (57.1)	162 (62.1)
Postmenopausal (%)	–	189 (68.6)
College graduate (%)	166 (30.2)	40 (15.3)
Smoking < 30 days ago (%)	183 (33.3)	85 (32.6)
Alcohol frequency > 1/month (%)	221 (40.2)	38 (14.6)

Continuous variables are shown as mean (SD); categorical variables are number (%)

219 unstable angina patients (27%). A family history of coronary artery disease or myocardial infarction among first-degree relatives was found in over half of cases (52%). In addition, cardiac risk factor profiles were typical of a population with ACS, with over one half of patients having hypercholesterolemia and hypertension, a third with history of smoking, and over one fifth with diagnosed diabetes. Previous revascularization had been performed in over a third of the cases.

There were 90 deaths in the cohort, which was followed for a mean of 39.1 months, with maximum follow-up time of 60 months. Risk factor data were missing for 2 individuals. There were marked differences in overall cardiac risk factor profiles, as expected, with deceased patients having relatively advanced age, as well as more extensive cardiovascular co-morbidity, including congestive heart failure (Table 2).


A total of 95 variants in 69 distinct genes or gene regions were genotyped. The average genotype call rate for these variants was 99.3%. Two assays failed (*FTO* rs9941349, *CETP* rs6499863). Eight variants violated HWE at the $P < 0.05$ level (additional file 1: Table S1).

The genotype distributions, numbers of deaths by genotypic category, and unadjusted *P* values for all 95 genetic variables are shown in additional file 1: Table S1, with the *P* value distributions summarized in the Q-Q plot shown in Figure 1. Overall, there were 4 positive associations ($P < 0.05$). Three of these associations did not retain statistical significance in a Cox proportional hazards adjusted model (rs6458545, $P = 0.36$; rs769449, $P = 0.41$; rs7754840, $P = 0.13$). However, the *MTHFD1L* association with mortality hazard remained statistically significant following adjustment for traditional cardiac risk factors. Of these covariates, age (HR 1.04/year; $P <$

Table 2 Clinical Characteristics of Surviving and Deceased Patients in the Follow-up Cohort

Characteristic	Survivors (N = 721)	Deceased (N = 90)
Mean age in years (SD)‡	60.5 (12.5)	69.5 (11.6)
Mean body mass index (SD)	29.4 (6.0)	28.8 (6.6)
Family history of CAD/MI (%)	374 (52.0)	40 (44.4)
Prior myocardial infarction(%)‡	176 (24.5)	40 (44.4)
Prior revascularization (%)‡	241 (33.5)	47 (52.2)
Congestive heart failure (%)‡	28 (3.9)	13 (14.4)
Hypertension (%)*	423 (58.8)	63 (70.0)
Diabetes Mellitus (%)‡	150 (20.9)	43 (47.8)
Hypercholesterolemia (%)	419 (58.3)	57 (63.3)
College graduate (%)	185 (25.9)	19 (21.6)
Smoking < 30 days ago (%)*	249 (34.7)	18 (20.0)
Alcohol frequency > 1/month (%)‡	348 (55.8)	19 (24.4)

Continuous variables are shown as mean (SD); categorical variables are number (%)



0.001), diabetes (HR 3.2; $P < 0.001$), prior myocardial infarction (HR 1.7; $P = 0.04$), congestive heart failure (2.0; $P = 0.04$), and unmarried status (HR 1.3; $P = 0.003$) had significant associations with mortality when modeled independent of genotype. The A/A genotype (versus G/G reference) of the mitochondrial-expressed *MTHFD1L* (methylene tetrahydrofolate dehydrogenase (NADP+ dependent) 1-like) gene variant rs6922269 was associated with hazard ratio of 2.6 ($P = 0.007$). The pairwise Kaplan-Meier analysis showed significant differences for the comparison of A/A vs G/G ($P = 0.01$), and A/G vs G/G ($P = 0.02$), but not A/A vs A/G ($P = 0.35$), implicating the A allele as a risk factor. Of the 12 A/A individuals who died (50% female), frequent co-morbidities were hypertension (N = 9), current or former smoking (N = 9), no current alcohol consumption (N = 9), hyperlipidemia (N = 8), family history of coronary

artery disease (N = 8), and type 2 diabetes (N = 7). However, the frequencies of such co-morbidities were not significantly different from the 78 other deceased patients with any other *MTHFD1L* rs6922269 genotype.


In order to limit multiple comparisons, only the *MTHFD1L* rs6922269 variant was brought forward for additional genotyping in the TRIUMPH cohort. In order to maximize power, the entire group of patients was subjected to combined Kaplan-Meier and Cox regression analysis. Characteristics, by genotype, of the entire study group appear in Table 3. As expected, mean follow-up time did not significantly differ by genotype. The A/A genotype of rs6922269 was strongly associated with all-cause mortality in the entire group (Figure 2; $P < 0.0001$). However, after adjustment for age, sex, and race, the hazard ratio for mortality in association with the A/A genotype was 1.35, with a borderline statistically significant P value of 0.052. Although sample size was too limited to document any formal trend towards increased mortality risk by number of A alleles, a suggestive decrement in risk was observed in Cox-adjusted hazard ratios, from 1.35 (A/A), to 1.21 (A/G) to 1.0 (G/G reference), as shown in Table 4. In the TRIUMPH replication cohort alone (N = 2284), a striking racial dichotomy was noted, with the lowest survival rate (81%) observed in African-American A/A homozygotes (additional file 1, Table S2), compared with 90% or greater survival in all other genotype categories for Whites and African-Americans. The difference in survival by genotype was statistically significant in African-Americans ($P = 0.015$) but not in Whites ($P = 0.284$).

Given the equivocal, but nominally statistically significant, results in our primary replication cohort, we collaborated with independent investigators to determine the

Table 3 Characteristics of patients by *MTHFD1L* genotype (N = 3095)

Outcome		GG (n = 1366)	AG (n = 1327)	AA (n = 402)	P Value
Patient Died	395 (12.8%)	137 (10.0%)	182 (13.7%)	76 (18.9%)	< 0.001
Time (Year)					0.120
Mean ± SD	2.8 ± 1.2	2.8 ± 1.1	2.7 ± 1.2	2.8 ± 1.4	
Median (IQR*)	2.7 (2.0, 3.6)	2.8 (2.1, 3.7)	2.6 (2.0, 3.6)	2.8 (1.8, 3.6)	
<i>Demographics and History</i>					
Age	59.3 ± 12.5	59.9 ± 12.2	59.1 ± 12.8	57.9 ± 12.4	0.010
Sex					0.003
Male	2095 (67.7%)	944 (69.1%)	909 (68.5%)	242 (60.2%)	
Female	1000 (32.3%)	422 (30.9%)	418 (31.5%)	160 (39.8%)	
Race Category					< 0.001
White/Caucasian	2315 (74.9%)	1189 (87.3%)	943 (71.1%)	183 (45.6%)	
Black/African American	607 (19.7%)	109 (8.0%)	303 (22.9%)	195 (48.6%)	
Other	167 (5.4%)	64 (4.7%)	80 (6.0%)	23 (5.7%)	
Unknown	6	4	1	1	

*IQR: interquartile range



extent to which our findings might be replicable in other cohorts of patients with CAD. Raw survival data are shown in Table 5. The overall proportion of deaths in all patients combined, by genotype, was essentially the same across all studies. Table 3 (additional file 1) presents the A allele frequency of the rs6922269 SNP of *MTHFD1L*, showing high similarity of race-specific allele frequencies across sites. Each site performed a standardized Cox proportional hazards analysis, stratified by race (if applicable) and adjusted for age and sex. The A/A genotype was not associated with mortality in any of the 3 independent cohorts. In the Emory cohort, among African-Americans with CAD, the A/A genotype hazard ratio (compared to G/G reference) was 1.126 (95% CI, 0.458 - 2.770; $p = 0.796$). Among whites, the HR was 0.684 (95% CI, 0.297 - 1.578; $p = 0.684$). Similar results for whites were obtained in the Cleveland Clinic cohort (A/A = 0.834 (95% CI, 0.402 - 1.728; $p = 0.624$) as well as the LURIC cohort (A/A = 0.846 (95% CI, 0.657 -

Table 4 Cox proportional hazards analysis involving all patients (N = 3095)

Variable	Hazard ratio	95% confidence interval	Chi-Square P
Age	1.05	(1.04-1.05)	< .0001
Male sex	1.05	(0.85-1.29)	0.66
Black race	2.56	(2.05-3.20)	< .0001
<i>MTHFD1L</i> A/A*	1.35	(1.00-1.82)	0.05
<i>MTHFD1L</i> A/G*	1.21	(0.97-1.52)	0.09

*Reference genotype G/G

1.090; $p = 0.196$), which had the longest follow-up of any study, with a median follow-up of 10.1 years. The corresponding median follow-up time in the Emory cohort was 2.4 years, and for Cleveland Clinic, it was 3 years.

Discussion

We initially found a nominally statistically significant association between the A/A genotype of *MTHFD1L* and mortality in an initial cohort of 811 white patients with ACS. However, in the primary replication cohort, as well as three additional replication cohorts of patients with MI and/or CAD, this association was not confirmed, with a total of over 9,000 patients studied.

Our experience in this study highlights that robust replication in multiple independent studies is a critical criterion for judging the validity of genetic associations. However, assembling the clinical data required to perform such replication studies is challenging, given that it may require not only the ascertainment of many thousands of patients, but also oversampling for minorities (by race and/or sex), and then tracking outcomes for many years. Our report of survival data for multiple high-priority SNPs advances the relatively neglected field of post-ACS genetic prognosis.

Although chance is the likely explanation for the apparently statistically significant association that we initially observed between mortality and rs6922269, other epidemiological factors should be considered in judging the cause-effect relationship between a putative risk factor and an outcome. In particular, prior evidence that the A allele is a risk factor for myocardial infarction is equivocal. Two major independent GWAS have reported the A allele of *MTHFD1L* to be associated with early-onset myocardial infarction [5,22]. First, the Wellcome Trust Case Control Consortium (WTCCC) reported a per-allele risk of 1.23 [1.15-1.33] for the A allele of rs6922269 and coronary artery disease, with a genome-wide statistical significance of 2.90×10^{-8} [22]. Subsequently, the transatlantic Coronary ARtery Disease Genome wide Replication and Meta-analysis (CARDIoGRAM) consortium performed a meta-analysis of 14 GWAS studies (22,233 cases, 64,763 controls), and *MTHFD1L* A risk allele not among the statistically significant genome-wide associations ($P = 7.38 \times 10^{-5}$; A frequency 0.28) [23]. The A allele was not associated with the presence of significant coronary arterial stenosis in a series of consecutive patients referred for coronary angiography due to known or suspected stable CAD [24].

Clearly, even findings that meet accepted genome-wide criteria for statistical significance in individual studies should be replicated widely before genetic associations are accepted as valid and robust. In addition, in

Table 5 Mortality, by MTHFD1L rs6922269 genotype, in all CAD cohorts (N = 9181)

cohort	race	G/G deaths	N	%	A/G deaths	N	%	A/A deaths	N	%
MAHI*	White	57	792	7.2	43	640	6.7	4	118	3.4
	AA†	11	127	8.8	29	307	9.4	29	166	17.5
Emory	White	68	927	7.3	49	654	7.5	6	110	5.5
	AA	8	106	7.5	17	221	7.7	12	132	9.1
Cleveland	White	76	1281	5.9	69	918	7.5	8	145	5.5
LURIC	White	489	1592	30.7	362	1227	29.5	72	219	32.9
Total		709	4825	14.7	569	3967	14.3	131	890	14.7

*Mid-America Heart Institute; †African-American

light of our study, it appears that realistic sample size calculations for prognostic studies may need to posit effect sizes at least as small as those that have emerged from GWAS studies of the occurrence of CAD, which are typically substantially less than 1.4. The challenge of mustering sufficient power is further amplified in prognosis studies by the fact that only a small proportion of patients will experience mortality within several years of follow-up. Therefore, sample size requirements for prognostic studies are expected to be at least as large as those for case-control studies. While it is beyond the scope of the present study to prescribe detailed sample size recommendations for future studies of prognosis in patients with common cardiovascular diseases, we would note that the CARDIOGRAM consortium included 22,233 patients with CAD, with an approximate 3:1 control-to-case ratio. In addition to requiring large sample sizes, considerations for oversampling clinically relevant subgroups, outcome adjudication, and genotyping scope and methods are all emerging challenges to field of cardiovascular genetics as it seeks to leverage genetic risk factors to better risk-stratify outcomes in AMI survivors. Additional limitations to this study include the heterogeneity of the present study, with respect to rs6922269 and our inability to discern whether or not there could be an effect in particular subgroups of patients, given the overall absence of a significant association.

Conclusions

We found no convincing support for the hypothesis that SNPs identified from GWAS studies of cardiac risk are associated with all-cause mortality following ACS, suggesting that independent GWAS studies of cohorts of many thousands of ACS patients may be required in order to identify prognostic factors in biological pathways promoting post-ACS mortality.

Additional material

Additional file 1: Tables S1-S3. Description of additional study populations. Genotyping methods in additional study populations.

Supplemental results in additional study populations. Supplemental Table 1. Supplemental Table 2. Supplemental Table 3.

Acknowledgements

This project was funded by grants from the Saint Luke's Hospital Foundation, Kansas City, MO, and by grants R-01 HS11282-01 from the Agency for Healthcare Research and Quality, Rockville, MD and P50 HL077113 from the National Heart, Lung and Blood Institute. Dr. Morgan's research was supported by a Mentored Patient-Oriented Research Grant (NHLBI K23 HI77272). These funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Dr. Morgan had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Author details

¹Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN USA. ²Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO USA. ³Department of Internal Medicine, Cardiovascular Division, Washington University School of Medicine, St. Louis, MO USA. ⁴Department of Preventive Medicine, USC Keck School of Medicine, Los Angeles, CA USA. ⁵Center for Cardiovascular Diagnostics and Prevention, Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. ⁶Emory University School of Medicine, Atlanta, GA, USA. ⁷Cardiff University, Cardiff, Wales, UK. ⁸NINDS/NIH, Bethesda, MD, USA. ⁹LURIC non profit LLC, Freiburg im Breisgau, Germany, and Mannheim Institute of Public Health, Medical Faculty Mannheim, University of Heidelberg, Germany. ¹⁰synlab Services GmbH, Mannheim, and Mannheim Institute of Public Health, Medical Faculty Mannheim, University of Heidelberg, Germany, and Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Austria. ¹¹Cardiology Group Sachsenhausen, Frankfurt Sachsenhausen, Germany. ¹²Division of Endocrinology, Diabetes and Metabolism, Graduate School of Molecular Diabetology and Endocrinology, Ulm University, Germany; ¹³Robert Wood Johnson Clinical Scholars Program and Department of Internal Medicine, Yale University School of Medicine, New Haven, CT USA.

Authors' contributions

TMM, HK, and JAS conceived of the study, and participated in its design and coordination and drafted the manuscript. TMM and SC performed genotyping for the primary study. JH and PJ participated in the design of the study and performed the statistical analysis. HA, SLH, YP, RSP, DJE, SPW, AAQ, MK, WM, BRW, and BOB executed all aspects of the replication studies and contributed data, statistical analysis, and critical input into the drafting of the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 27 October 2010 Accepted: 29 September 2011

Published: 29 September 2011

References

- Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorf LA, Hunter DJ, McCarthy ML, Ramos EM, Cardon LR, Chakravarti A, et al: **Finding the missing heritability of complex diseases.** *Nature* 2009, **461**(7265):747-753.
- Wellcome Trust Case Control Consortium: **Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls.** *Nature* 2007, **447**(7145):661-678.
- Dorn GW, Cresci S: **Genome-wide association studies of coronary artery disease and heart failure: where are we going?** *Pharmacogenomics* 2009, **10**(2):213-223.
- Erdmann J, Grosshennig A, Braund PS, König IR, Hengstenberg C, Hall AS, Linsel-Nitschke P, Kathiresan S, Wright B, Tregouet DA, et al: **New susceptibility locus for coronary artery disease on chromosome 3q22.3.** *Nat Genet* 2009, **41**(3):280-282.
- Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM, Anand S, Engert JC, Samani NJ, Schunkert H, et al: **Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants.** *Nat Genet* 2009, **41**(3):334-341.
- McCarthy ML, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, Hirschhorn JN: **Genome-wide association studies for complex traits: consensus, uncertainty and challenges.** *Nat Rev Genet* 2008, **9**(5):356-369.
- Morgan TM, Krumholz HM, Lifton RP, Spertus JA: **Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study.** *Jama* 2007, **297**(14):1551-1561.
- Alpert JS, Thygesen K, Antman E, Bassand JP: **Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction.** *J Am Coll Cardiol* 2000, **36**(3):959-969.
- Braunwald E: **Unstable angina. A classification.** *Circulation* 1989, **80**(2):410-414.
- Schisterman EF, Whitcomb BW: **Use of the Social Security Administration Death Master File for ascertainment of mortality status.** *Popul Health Metr* 2004, **2**(1):2.
- Salisbury AC, Kosiborod M: **Outcomes associated with anemia in patients with heart failure.** *Heart Fail Clin* 6(3):359-372.
- Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, et al: **Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.** *JAMA* 2008, **299**(11):1265-1276.
- Nicholls SJ, Tang WH, Scoffone H, Brennan DM, Hartiala J, Allayee H, Hazen SL: **Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy.** *J Lipid Res* 51(10):3055-3061.
- Patel RS, Su S, Neeland IJ, Ahuja A, Veledar E, Zhao J, Helgadottir A, Holm H, Gulcher JR, Stefansson K, et al: **The chromosome 9p21 risk locus is associated with angiographic severity and progression of coronary artery disease.** *Eur Heart J* 31(24):3017-3023.
- Winkelmann BR, Marz W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J: **Rationale and design of the LURIC study—a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease.** *Pharmacogenomics* 2001, **2**(1 Suppl 1):S1-73.
- Dean FB, Hosono S, Fang L, Wu X, Faruqi AF, Bray-Ward P, Sun Z, Zong Q, Du Y, Du J, et al: **Comprehensive human genome amplification using multiple displacement amplification.** *Proc Natl Acad Sci USA* 2002, **99**(8):5261-5266.
- Yan J, Feng J, Hosono S, Sommer SS: **Assessment of multiple displacement amplification in molecular epidemiology.** *Biotechniques* 2004, **37**(1):136-138, 140-133.
- Morgan TM, Xiao L, Lyons P, Kassebaum B, Krumholz HM, Spertus JA: **Investigation of 89 candidate gene variants for effects on all-cause mortality following acute coronary syndrome.** *BMC Med Genet* 2008, **9**:66.
- Yuan A, Bonney GE: **Exact test of Hardy-Weinberg equilibrium by Markov chain Monte Carlo.** *Math Med Biol* 2003, **20**(4):327-340.
- Perneger TV: **What's wrong with Bonferroni adjustments.** *Brmj* 1998, **316**(7139):1236-1238.
- Dupont WD, Plummer WD Jr: **Power and sample size calculations for studies involving linear regression.** *Controlled clinical trials* 1998, **19**(6):589-601.
- Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, et al: **Genomewide association analysis of coronary artery disease.** *The New England journal of medicine* 2007, **357**(5):443-453.
- Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, et al: **Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease.** *Nat Genet* 43(4):333-338.
- Muendlein A, Saely CH, Rhomberg S, Sonderegger G, Loacker S, Rein P, Beer S, Vonbank A, Winder T, Drexel H: **Evaluation of the association of genetic variants on the chromosomal loci 9p21.3, 6q25.1, and 2q36.3 with angiographically characterized coronary artery disease.** *Atherosclerosis* 2009, **205**(1):174-180.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2350/12/127/prepub>

doi:10.1186/1471-2350-12-127

Cite this article as: Morgan et al.: Investigation of 95 variants identified in a genome-wide study for association with mortality after acute coronary syndrome. *BMC Medical Genetics* 2011 **12**:127.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

